There are 2934 resources available
Present standard of care according to the 2019 ESMO Guidelines
Presenter: Manuela Schmidinger
Session: ESMO Colloquium supported by Ipsen - Metastatic clear cell renal cell carcinoma How to navigate within multiple options and risk groups? What is the best sequence in a multi-line setting?
Resources:
Slides
Webcast
Comparative outcome in 1st line according to prognostic group and criteria for decision making
Presenter: Camillo Guglielmo Porta
Session: ESMO Colloquium supported by Ipsen - Metastatic clear cell renal cell carcinoma How to navigate within multiple options and risk groups? What is the best sequence in a multi-line setting?
Resources:
Slides
Webcast
Options and criteria for treatment choice in 2nd and 3rd lines
Presenter: Ronald de Wit
Session: ESMO Colloquium supported by Ipsen - Metastatic clear cell renal cell carcinoma How to navigate within multiple options and risk groups? What is the best sequence in a multi-line setting?
Resources:
Slides
Webcast
How to the sequence the use of drugs in a multi-lines’ strategy for RCC?
Presenter: Bernard Escudier
Session: ESMO Colloquium supported by Ipsen - Metastatic clear cell renal cell carcinoma How to navigate within multiple options and risk groups? What is the best sequence in a multi-line setting?
Resources:
Slides
Webcast
4878 - Next-generation sequencing (NGS) in metastatic colorectal cancer (mCRC): novel mutated genes and their effect on response to therapy (Alliance)
Presenter: Federico Innocenti
Session: Proffered Paper 2 – Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
LBA32 - Encorafenib plus Cetuximab With or Without Binimetinib for BRAF V600E–Mutant Metastatic Colorectal Cancer: Expanded Results from a Randomized, 3-Arm, Phase III Study vs. the Choice of Either Irinotecan or FOLFIRI plus Cetuximab (BEACON CRC)
Presenter: Josep Tabernero
Session: Proffered Paper 2 – Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
1890 - MIRACLE: Green tea extract versus placebo for the prevention of colorectal adenomas: a randomized, controlled trial
Presenter: Thomas Seufferlein
Session: Proffered Paper 2 – Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
4580 - Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042
Presenter: Aaron Mansfield
Session: Proffered Paper 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
3200 - CTONG 1509 : Phase 3 study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC
Presenter: Qing Zhou
Session: Proffered Paper 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1783 - Clinical development of molecular-targeted therapies for non-small cell lung cancer through nationwide genome screening in Japan (LC-SCRUM-Japan)
Presenter: Shingo Miyamoto
Session: Proffered Paper 2 - NSCLC, metastatic
Resources:
Abstract
Slides